|
11. |
An Investigation Into Variability in the Therapeutic Response to Deferiprone in Patients With Thalassemia Major |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 74-81
Orna Diav-Citrin,
Gordana Atanackovic,
Gideon Koren,
Preview
|
|
摘要:
Data suggest a large variability in the effectiveness of the orally active iron chelator, deferiprone, in inducing a sustained decrease in body iron to concentrations compatible with the avoidance of complications from iron overload. We analyzed 19 patients with thalassemia major who were undergoing long-term therapy with deferiprone (75 mg/kg/day every 8 hours). In seven of the 19 patients, hepatic iron concentration had been reduced or maintained at less than 7 mg/g of dry weight liver tissue, associated with no evidence of iron-induced toxicity (group A). In the remaining 12, hepatic iron concentration had either stabilized at higher than 7 mg/g of dry weight liver tissue, or increased to such concentrations during therapy with deferiprone (group B). We studied in these patients determinants that may explain such variability, including initial hepatic iron concentrations, compliance, transfusion index, pharmacokinetic characteristics of deferiprone, and plasma vitamin C status. Patients in group B showed significantly decreased plasma vitamin C concentrations compared with those in group A, who demonstrated normal levels (0.04 mg/dl [0.04-0.19 mg/dl] and 0.62 mg/day [0.44-1.05 mg/day], respectively;p= 0.02). A significant difference in apparent volume of distribution (Vd/F) had developed between the groups over time, with a higherVd/F in group B (1.66 [0.681, group A] and 3.16 [0.811, group B];p= 0.006). Group B had started with hepatic iron concentrations that were significantly higher than those of group A, a difference that became more pronounced over time. In the initial analysis, serum ferritin concentrations were also higher in group B. The two groups did not differ in the remaining factors. The initial hepatic iron concentrations predicted the slope of change in this value. Regression analysis suggested that patients with initial hepatic iron concentration of less than or equal to 7.22 mg/g of dry weight liver tissue are unlikely to further decrease while taking deferiprone 75 mg/kg/day. Vitamin C deficiency developed in patients in group B over time. Vitamin C is an important biologic cofactor that plays a role in the distribution of iron. The trend of increase inVd/F of deferiprone over time may imply a compartment shift of iron stores to one less accessed by deferiprone. This study confirmed the effectiveness of deferiprone in heavily iron-loaded patients and provided evidence that its effectiveness decreases in proportion to liver iron load.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
12. |
Interindividual Variation of Plasma Haloperidol Concentrations and the Impact of Concomitant Medications: The Analysis of Therapeutic Drug Monitoring Data |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 82-86
Genta Hirokane,
Toshiyuki Someya,
Saburo Takahashi,
Sachiyo Morita,
Kazutaka Shimoda,
Preview
|
|
摘要:
We analyzed therapeutic drug monitoring (TDM) data from 231 schizophrenic inpatients (137 men, 94 women) and investigated interindividual differences of plasma haloperidol (HAL) concentrations and drug/drug interactions between HAL and various concomitant drugs. Plasma HAL concentrations were determined by an enzyme immunoassay (EIA) method. Plasma HAL concentrations per daily dose of HAL per body weight (HAL C/D ratio) demonstrated an approximately 11-fold interindividual variation. The patient subjects who received carbamazepine (CBZ) concomitantly had a mean HAL C/D ratio that was 37% lower than that of the patient subjects without CBZ. The patient subjects treated with concomitant phenobarbital (PB) also showed a mean HAL C/D ratio that was 22% lower than those without PB. We concluded that careful evaluation of HAL TDM data and consideration of the impact of concomitant medication such as CBZ or PB that might influence the metabolism of HAL is necessary in daily clinical settings to avoid insufficient clinical response because of lowered concentrations of HAL or adverse effects because of high concentrations of HAL.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
13. |
Olanzapine Serum Concentrations in Psychiatric Patients Given Standard Doses: The Influence of Comedication |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 87-90
Ole Olesen,
Kristian Linnet,
Preview
|
|
摘要:
We recorded steady state serum concentrations of olanzapine in 56 psychiatric patients under routine conditions. Twenty-two patients (39%) underwent monotherapy; the rest received additional psychotropic drugs. Doses were given once daily in the evening, and serum olanzapine levels were measured 12 hours later. For the whole group, the concentration-to-dose ratio (C/D) varied 26-fold, with a median value of 4.8 (nmol/L)/(mg/24 hours), but 80% of the patients had C/D values within the range 2 to 10 (nmol/L)/ (mg/24 hours). All but three patients received standard doses (5-20 mg/24 hours), of whom 80% had serum concentrations of olanzapine within the range 22 to 146 nmol/L. Patients comedicated with potential inhibitors of CYP2D6 and other drugs displayed a median C/D approximately 40% higher than the group undergoing monotherapy. Patients comedicated with carbamazepine had a median C/D 36% lower than that of the monotherapy group. Therefore, the serum concentration range (12-hour values) of 25 to 150 nmol/L can be expected for patients receiving a standard daily dose.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
14. |
Valproate Monotherapy in Juvenile Myoclonic Epilepsy: Dose-Related Effects on Electroencephalographic and Other Neurophysiologic Tests |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 91-96
Anders Sundqvist,
Bengt Nilsson,
Torbjörn Tomson,
Preview
|
|
摘要:
A neurophysiologic test battery (consisting of a 24-hour, seven-channel electroencephalogram [EEG], EEG spectral analysis, multiple sleep latency test, visual evoked potentials, critical flicker fusion, and visual contrast sensitivity) was administered twice to 16 patients with juvenile myoclonic epilepsy (JME) in a double-blind, randomized, crossover study comparing two daily doses of sodium valproate (VPA), 1000 mg and 2000 mg. Clinical observation time was 6 months for each dose. Mean total VPA concentration during low-dose treatment was 470.4 mmol/L and during high-dose treatment was 700.0 mmol/L. Ten patients had seizures during low-dose treatment, but only three of these showed spike-wave activity on EEGs. During high-dose treatment, nine patients had seizures; five of these had spike-wave activity. EEG power spectrum did not change between doses. The other tests also showed no change between doses. Our results suggested that EEG and our selection of other neurophysiologic tests were of limited value for monitoring seizure frequency and clinical effects of VPA.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
15. |
Biologic Variation of Serum and Salivary Lithium |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 97-101
J. Moody,
Preview
|
|
摘要:
Within- and between-subject variability in serum and salivary lithium concentrations in nine psychiatric inpatients on stable drug regimens undergoing therapy has been assessed using criteria for determining biologic variation. This allows separation of analytic from other measures of variance. There were marked differences in inter- and intra-subject variance for serum and salivary lithium concentrations for serum/salivary ratios. Moreover, these variances were greater for salivary lithium than for serum concentrations. The results have been used to assess analytical performance, the usefulness of the therapeutic range, and the reference change interval. Despite greater variance for salivary concentrations, predicted serum concentrations from predetermined serum/saliva ratios were in good agreement with actual concentrations in most subjects.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
16. |
Sampling Technique From Central Venous Catheters Proves Critical for Pharmacokinetic Studies |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 102-104
Alwin D. R. Huitema,
Marjo Holtkamp,
Matthÿs Tibben,
Sjoerd Rodenhuis,
Jos Beijnen,
Preview
|
|
摘要:
Double-lumen central venous access (CVA) catheters are occasionally used in pharmacokinetic studies for drug administration and blood sampling. The samples are often collected by the nursing staff and thus the investigator may not be aware of the specific sampling technique used. We present an example of the dramatic effect that an incorrect sampling technique from double-lumen CVA catheters can have on pharmacokinetic outcomes. Using a double-lumen Hickman catheter (Poly-Cath Central Venous Catheter; Strato Medical Corporation/Infusaid Inc., Manchester, GA, U.S.A), sampling during the infusion can be performed when the infusion is connected to the lumen with the end most downstream and blood is collected from the proximal opening. With a normal double-lumen catheter, sampling can only be performed by briefly interrupting the infusion or after the infusion.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
17. |
Therapeutic Drug Monitoring of Risperidone Using a New, Rapid HPLC Method: Reappraisal of Interindividual Variability Factors |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 105-115
Androniki Balant-Gorgia,
Marianne Gex-Fabry,
Chantal Genet,
Luc Balant,
Preview
|
|
摘要:
Because of the enormous gap between premarketing studies in physically healthy subjects and clinical practice in patients, the present study reconsidered interindividual variability factors affecting risperidone concentrations under routine therapeutic drug monitoring conditions. The study included 92 patients, 27% of whom were 70 years or older. The patients received risperidone orally (dose range, 0.5-11 mg per day) and had concentrations of risperidone and the active metabolite 9-hydroxyrisperidone measured at steady state by a new, rapid, and sensitive method of high-performance liquid chromatography (HPLC). After normalization to a dose of 4 mg/day, median concentrations were 2.9 ng/ml (80% range, 0.9-27.9 ng/ml) for the parent compound and 24.1 ng/ml (80% range, 12.0-57.6 ng/ml) for the metabolite. When considering linear regression models, age was identified as a major source of interindividual variability, with expected increases of 340% and 220% for concentrations of parent compound and metabolite, with age increasing from 20 to 80 years. Body weight provided an additional significant contribution to the variability of 9-hydroxyrisperidone concentration, a 20-kg higher body weight associated with a concentration decrease of 23%. Serotonin-specific reuptake inhibitor (SSRI) comedication (fluoxetine, two patients; citalopram, two patients; paroxetine, one patient; fluvoxamine, one patient) was significantly associated with 4.6-fold higher concentrations of parent compound, in keeping with an inhibitory action on CYP2D6 enzyme. Significantly higher concentrations of 9-hydroxy-risperidone (+ 29%) were also observed in the 17 patients with biperiden comedication. Therapeutic drug monitoring data, collected in patients representative of the population for which the drug was intended, allowed us to quantify the dose reduction needed in elderly patients and thus provided valuable information in addition to the one collected during premarketing studies performed with strict inclusion and exclusion criteria.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
18. |
LC/ESI-MS Allows Simultaneous and Specific Quantification of SDZ RAD and Cyclosporine, Including Groups of Their Metabolites in Human Blood |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 116-122
Gabriele Kirchner,
Christian Vidal,
Michael Winkler,
Lueke Mueller,
Wolfgang Jacobsen,
Anke Franzke,
Karl-Friedrich Sewing,
Preview
|
|
摘要:
An analytic technique using liquid chromatography (LC) coupled with electrospray-mass spectrometry (ESI-MS) has been developed for the simultaneous determination of the new immunosuppressant SDZ RAD (40-O-[2-hydroxy)ethyl-rapamycin) and cyclosporine (Cs), including their metabolites in blood. With the time-sparing, automated on-line extraction technique, the recovery of SDZ RAD averaged 95% and that of Cs, 94%. The calibration lines were linear from 0.5 to 100 µg/L (r2 = 0.99) for SDZ RAD and from 10 to 1,000 µg/L (r2 = 0.99) for Cs. The method has been tested on blood samples from renal transplant recipients taken between 1 and 5 hours after oral SDZ RAD and Cs administration. In blood, we found the following metabolites: Hydroxy-SDZ RAD, dihydroxy-SDZ RAD, demethyl-SDZ RAD, and the ring-opened form of SDZ RAD. The main metabolite of SDZ RAD in blood was hydroxy-SDZ RAD. This novel LC/ESI-MS technique provided an excellent method for simultaneous quantitative monitoring of SDZ RAD and Cs, including their relevant groups of metabolites in patients treated simultaneously with these immunosuppressants,
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
19. |
Analytic Performance of Two Automated Nonpretreatment Digoxin Immunoassays |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 123-128
Barun De,
Dena Booth,
Pamela Magee,
Marcia Moore,
Teresa Preuss,
T. Rose,
William Roberts,
Preview
|
|
摘要:
The analytic performance of two automated nonpretreatment digoxin methods, AxSYM Digoxin II and Vitros digoxin immunoassays, was assessed. Both assays had analytic sensitivites of less than 0.2 µg/L, were linear from digoxin concentrations of 0.5 to 4.0 µg/L, and showed acceptable precision, with a maximum total coefficient of variation (CV) of 8.9% and 6.4% for the AxSYM and Vitros, respectively. Comparison of the two methods using samples from patients receiving digoxin gave the following relationship: Vitros = 0.91 × AxSYM + 0.23 (r= 0.97, Sy,x= 0.12). Digoxinlike immunoreactive factor (DLIF) crossreactivity was examined in specimens from patients who had hepatic disease, renal insufficiency, had undergone cardiac surgery, and in neonatal cord blood samples. Minimal crossreactivity was observed for most samples and the average crossreactivity for each group of samples was comparable for the two methods. The recovery of digoxin added to samples from each group of DLIF was similar, except for that from cord blood samples, for which recovery was significantly lower with the AxSYM method. Titration of a digoxin-spiked serum pool with digoxin-immune Fab showed a similar decrease in the measured digoxin concentration for both methods. Overall, the analytic performance characteristics of these two methods were comparable.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
20. |
Determination of Acyclovir in Plasma by Solid-Phase Extraction and Column Liquid Chromatography |
|
Therapeutic Drug Monitoring,
Volume 21,
Issue 1,
1999,
Page 129-133
Jean-Marie Poirier,
Nathalie Radembino,
Patrice Jaillon,
Preview
|
|
摘要:
After oral administration, valacyclovir, the L-valyl ester of acyclovir, converts to the antiherpes virus drug, acyclovir. The bioavailability of acyclovir after valacyclovir administration is between 3- to 4.5-fold higher than that achieved after oral acyclovir administration. Therefore, despite the drug's short terminal half-life (3 hours), acyclovir plasma concentrations obtained after oral administration of the pro-drug offer a more convenient dosage regimen in patients with herpes zoster than that required after acyclovir administration. Acyclovir is also used for viral infection prophylaxis in patients with hematologic disorders and in those who have undergone solid organ transplantation. We have described a simple and selective liquid chromatographic method for the determination of acyclovir in plasma using a new polymeric reversed-phase sorbent for solid-phase extraction. A mean acyclovir absolute recovery of 90% was found after elution of the drug from the cartridge with the mobile phase. This procedure allowed us to measure 62.5 ng/mL of acyclovir with an acceptable precision using a plasma volume of 250 µL, and no drug was found to interfere with the assay. This method is suitable for the therapeutic monitoring of acyclovir in patients who have been given a wide variety of coadministered drugs.
ISSN:0163-4356
出版商:OVID
年代:1999
数据来源: OVID
|
|